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eVIdence of PHosPHoRYlAtIon
Name Phosphorylation site In cells  Inhibitor Mutation Interaction Effect of phosphorylation
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ATF2 T69P, T71P Endogenous  +   yes CoIP Activation of transcription
C/EBPβ n/d Overexpressed  +   n/d  Activation of  transcription 
CHOP-GADD153-DDIT3 S79P, S82P Endogenous +  yes  Activation of  transcription 
ERa-ESR1  T311A Endogenous   +/-   yes  Activation of transcription
Fos–c-fos T325P Overexpressed  +   yes  Activation of transcription
FOXO3a S7P Overexpressed  +    n/d CoIP Nuclear translocation 
Jun–c-Jun S63P, S73P n/d  +    n/d  Activation of transcription
MafA T57P, T134P, S336P Overexpressed  +    yes  Activation of transcription
MEF2A T312P, T319P, S453P Endogenous  +    yes  Activation of transcription
MEF2C  T293P, T300P, S387P Overexpressed n/d yes Y2H, PD Activation of transcription
MITF  S307P Overexpressed  +    yes  Activation of transcription
MRF4-MYF6 S31P, S42P Overexpressed  +    yes CoIP Inhibition of transcription
p53-TP53 S15Q, S33P, S37Q, S46P Endogenous  +    yes CoIP Activation of transcription
Smad3 n/d n/d  +    n/d  Nuclear translocation 
STAT1 S727P Endogenous  +    yes  Activation of transcription
STAT4 S721P Overexpressed  +    yes  Activation of transcription
USF1 T153P Endogenous  +    yes  Activation of transcription
Xbp1s T48P, S61P (m) Overexpressed  +    yes  Nuclear translocation
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BAF60c T229P Endogenous  +    yes  Activation of  transcription 
Cdt1 n/d Overexpressed n/d yes CoIP Protein stabilization by blocking binding to Cdt2
E47-TCF3 S139P Overexpressed  +    yes CoIP Formation of MyoD/E47 heterodimers  
H2AX S140Q Endogenous  +    n/d  Induction of apoptosis
H3-H3F3A S11T Endogenous  +    n/d  Posible contribution to transcriptional activation
HBP1 S402P n/d n/d yes CoIP, Y2H Protein stabilization; repression of transcription
p18Hamlet-ZNHIT1 T6S, T64G, T71R, T103A Overexpressed  +    yes Y2H, PD Protein stabilization; activation of transcription
PGC-1a T263P, S266P, T299P Overexpressed  +    yes  Activation of transcription
Rb1 S567P Endogenous  +    n/d  Protein degradation via Hdm2; release of E2F1 
SRC3-NCOA3 S860P Overexpressed n/d n/d  Protein degradation; inhibition of transcription
R
N
A
 b
in
d
in
g FBP2/3 n/d Overexpressed n/d n/d  Prothrombin mRNA 3´ end processing and translation
HuR-ELAVL1 T118Q Overexpressed   n/d    yes  Cytoplasmic accumulation; enhanced mRNA binding
KSRP T692P Overexpressed  +    yes CoIP Enhanced mRNA stability
SPF45-RBM17 T71P, S222P Overexpressed  +    n/d CoIP Decreased exon 6 exclusion in Fas mRNA
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GSK3β T390P Endogenous  +    yes CoIP Kinase inactivation
MK2-MAPKAPK2 T25P, T222P, T272P, S334P Endogenous  +    yes CoIP Kinase activation 
MK5-PRAK-MAPKAPK5 T182P Endogenous  +    yes Y2H, CoIP Kinase activation
Mnk1-MKNK1 T385P Endogenous  +    n/d Y2H, CoIP Kinase activation
Mnk2-MKNK2 S74F Overexpressed  +    n/d Y2H Kinase activation
Msk1-RPS6KA4 S360P, T581P Overexpressed  +    yes CoIP Kinase activation
PKCε S350P Overexpressed  +    yes  Association with 14-3-3; completion of cytokinesis
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BimEL-BCL2L11 S69P Endogenous  +    yes  Induction of apoptosis
Caspase-3-CASP3 S150L Endogenous  +/-    yes CoIP Inhibition of protease activity; reduced apoptosis
Caspase-8-CASP8 S347L Endogenous  +/-    yes CoIP Inhibition of protease activity; reduced apoptosis
Cdc25A S76S, S124D Overexpressed  +   yes  Protein stabilization; enhanced phosphatase activity
Cdc25B S249P n/d  +   yes  Protein stabilization; enhanced phosphatase activity
Cyclin D1-CCND1 T156P, T286P n/d  +/-    yes  Protein degradation; CDK inactivation
Cyclin D3-CCND3 T283P n/d  +    n/d  Protein degradation; CDK inactivation
FLIPs-CFLAR  S4P (m) Endogenous  +    yes CoIP Protein degradation via interaction with c-Cbl
GS-GYS1 S645P Overexpressed  +    yes PD
Posible contribution to inhibition of glycogen syntase 
activity
JIP4-SPAG9 n/d n/d  +    yes PD Enhanced p38 MAPK activation
p47phox-NCF1 S345P, S348P Endogenous  +    yes  Activation of NADPH oxidase; superoxide production
p57kip2-CDKN1C T143P Overexpressed  +    yes CoIP Enhanced binding to CDK; inhibition of CDK activity
PIP4Kβ-PIP4K2B S326P Endogenous  +    yes  
Decreased lipid kinase activity; nuclear accumulation of 
PI5P
Rpn2-PSMD1 T273P Endogenous +/- yes  Inhibition of proteasome activity
Siah2 T24P, S29P (m) n/d  +    yes  Increased ubiquitination; degradation of PHD3
Tab1 S423A, T431P, S438P Endogenous  +    n/d Y2H, CoIP Inhibition of TAK1 kinase activity
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EGFR T669P Overexpressed  +    yes  Internalization of Tyr kinase receptor
FGFR1 S777P Endogenous  +    yes  Internalization of Tyr kinase receptor; nuclear translocation
Nav1.6-SCN8A S553P n/d n/d    n/d  Reduced densitity of channel in membrane
NHE1 n/d Overexpressed  +    n/d CoIP Intracellular alkalinization
TACE-ADAM17 T735P Endogenous  +    yes CoIP Protease activation; ectodomain shedding of TGFα 
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EEA1 T1392P Overexpressed  +    yes  Recruitment to endocytic membranes
GDI-2 S121T n/d n/d    yes  Formation of the GDI-Rab5 complex
Rabenosyn5-ZFYVE20 S215P Overexpressed  +    yes  Recruitment to endocytic membranes
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Hsp27-HSPB1 n/d Overexpressed  +    n/d  n/d
Keratin 8 S74P Endogenous  n/d     yes    CoIP   Reorganization of cytoskeleton fi laments
Lamin B1 n/d n/d n/d   n/d CoIP Lamin B1 accumulation in nucleus
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The ability of p38a mitogen-activated protein kinase (MAPK14) to phosphorylate many downstream substrates allows this pathway to regulate a wide variety of cellular pro-
cesses. Thus, based on the nature of the substrates phosphorylated by p38a, cells can decide whether to live or die or whether they should engage into specific programs of 
growth, proliferation, or differentiation. All p38a-mediated phosphorylations have been reported to occur on Ser or Thr residues, which are usually followed by a Pro residue. 
Consistent with this notion, about 85% of the p38a phosphorylation sites described so far correspond to Ser-Pro or Thr-Pro motifs (see Table S1 available online). Intriguingly, 
Ser-Pro/Thr-Pro sites are extremely common and thus most human proteins could be potential p38a substrates. Therefore, it is clear that additional substrate recognition 
mechanisms should be involved to ensure signaling fidelity.
A key aspect of kinase-substrate recognition is based on the interaction of the kinase catalytic cleft with the target phosphor-acceptor residue. However, some substrates 
also contain specific binding regions referred to as docking sites, which are not related to the phosphorylation sites but play key roles in efficient substrate phosphorylation. 
The best-characterized MAPK docking site is the D domain, which consists of two or more basic residues and a stretch of hydrophobic residues with a short linker in between. 
Nevertheless, it is important to note that many p38a substrates do not seem to contain docking domains. In these cases, it is likely that substrate selection depends on other 
determinants such as availability, concentration, and subcellular localization. There is evidence that p38a can be detected in both the cytoplasm and the nucleus, suggesting the 
existence of different pools of p38a that could be specifically targeted by particular stimuli. The availability of binding partners may also impinge on p38a subcellular localiza-
tion. Another factor that is likely to influence substrate determination is the strength and duration of p38a activity in the cell. Altogether, the pool of substrates phosphorylated 
by p38a in each case will provide the cell with information required to orchestrate the adequate response.
The table, a companion to the SnapShot “p38 MAPK Signaling” in the January 31 issue of Cell, shows 66 p38a substrates that are divided into eight different groups based 
on biochemical function. All indicated proteins have been shown to be directly phosphorylated by p38a in vitro, using either recombinant or immunoprecipitated p38a. In most 
cases, residues phosphorylated by p38a have been mapped. Numbers refer to the human proteins except for the three cases indicated by (m), which are mouse proteins. n/d, 
not determined. We have also analyzed the published data, paying special attention to the supporting evidence of phosphorylation and functional consequences.
Many substrates have been validated in vivo using either generic or specific phospho-antibodies. “In cells” refers to the detection of the phosphorylation events in either over-
expressed or endogenous proteins of mammalian cells. “Inhibitor” refers to the use of chemical compounds—mainly SB203580 or SB202190—to impair substrate phosphoryla-
tion in cells. “+” indicates that inhibitors were used at 10 mM or lower concentration; “+/-” indicates that inhibitors were used at >10 mM. “Mutation” indicates that phosphorylation 
sites were confirmed by mutation of the corresponding residues. Some substrates have been reported to interact with p38a based on coimmunoprecipitation (CoIP), yeast 
two-hybrid (Y2H), or pull-down (PD) experiments. The effects produced on the substrates by p38a phosphorylation are also indicated.
A future challenge will be to identify the set of proteins that are phosphorylated upon p38a activation in different contexts, which should help to elucidate how cells respond 
to multiple extracellular signals and changing environmental conditions.
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